The chief scientific officer at Candel Therapeutics discussed late-breaking data presented at ASGCT 2023.
“We had previously disclosed the data from ARM A, and this is an expansion cohort, where patients prior to the injection of CAN-3110 gets a pretreatment with... We had some animal data that seems to suggest that this pretreatment was making the viral replication more efficient, and [in the trial] we saw results very similar to arm A, so this really works as an independent cohort that confirms our previous data. We have a median overall survival of 12 months, and this exceeds the median overall survival of the approved drugs in this space.”
Data from the first 50 participants with recurrent high-grade glioma (rHGG) treated with a single intratumoral injection of Candel Therapeutics’ CAN-3110 (also known as rQNestin34.5v.2), a Herpes simplex virus-1 oncolytic viral immunotherapy, tolerated the treatment well and had promising signals of efficacy and survival benefits.
These data, from a phase 1/2 study (NCT03152318), were presented during a late-breaking session at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California, by Francesca Barone, MD, PhD, chief scientific officer, Candel Therapeutics.
CGTLive spoke with Barone to learn more about the new data seen with CAN-3110 treatment in patients with rHGG. She shared some highlights from her presentation, including a 12-month median overall survival, which is higher than that seen with approved drugs in the space. She also discussed positive biomarker data from the study, such as finding vectors from CAV-3110 within non-injected, shrinking, tumor lesions.